Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Capitalization 124B P/E ratio 2024 *
30.9x
P/E ratio 2025 * 28.7x
Enterprise value 115B EV / Sales 2024 *
8.12x
EV / Sales 2025 * 7.18x
Free-Float
79.08%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.44%
1 week-2.41%
Current month-2.88%
1 month+7.40%
3 months+14.38%
6 months+19.20%
Current year+31.00%
More quotes
1 week
1 143.25
Extreme 1143.245
1 192.54
1 month
1 061.46
Extreme 1061.46
1 211.20
Current year
871.39
Extreme 871.39
1 211.20
1 year
769.19
Extreme 769.19
1 211.20
3 years
538.01
Extreme 538.01
1 211.20
5 years
271.37
Extreme 271.37
1 211.20
10 years
271.37
Extreme 271.37
1 211.20
More quotes
Director TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 53 02-12-31
Manager TitleAgeSince
Chief Executive Officer 71 88-01-07
Director/Board Member 83 91-05-31
Director/Board Member 83 91-05-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-2.44%-2.41%+39.82%+69.31%124B
-2.09%-5.02%+34.55%+136.59%121B
+3.58%+2.57%+1.46%+64.85%32.24B
+1.27%+2.91%-26.11%-73.03%21.43B
+1.55%-3.49%-6.47%-43.04%20.35B
-0.08%-0.67%-29.89%-39.09%17.59B
+0.66%+2.45%-51.28%-70.34%15.84B
-3.11%-4.48%+176.49%+155.73%12.53B
-0.76%-2.54%+10.95%+66.15%12.76B
-1.09%-5.62%+10.26%+26.43%12.24B
Average -0.25%-1.75%+15.98%+29.36% 39.01B
Weighted average by Cap. -1.11%-2.52%+24.65%+66.89%
See all sector performances
2024 *2025 *
Net sales 14.15B 15.37B
Net income 4.23B 4.43B
Net Debt -9.25B -13.9B
More financial data * Estimated data
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Employees
13,926
Related indices
More about the company
Date Price Change Volume
24-09-05 1,150.56 $ -2.44% 534,411
24-09-04 1,179.37 $ +0.90% 333,049
24-09-03 1,168.81 $ -1.34% 579,321
24-08-30 1,184.69 $ +0.49% 405,354
24-08-29 1,178.93 $ -1.70% 538,650

Delayed Quote Nasdaq, September 05, 2024 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
1,150.56USD
Average target price
1,153.73USD
Spread / Average Target
+0.28%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW